Automation in the mechanics of pharmaceutical crystallization

Crystallization remains one of the most resource-intensive stages of pharmaceutical manufacturing, governed by the interlocking complexities of thermodynamics and kinetics. A joint review from researchers at MIT and Amgen identifies a shift toward integrated automation to manage these variables. While process analytical technology has existed for years, the industry is now moving toward a unified stack where algorithmic experiment-selection software directs the physical mapping of the design space.

The challenge for automation in this sector lies in the nonlinear nature of crystal growth and multiphase behavior. Developing a robust process traditionally requires exhaustive manual screening to ensure solid-form selection and purity. The current trajectory focuses on using machine learning to predict these behaviors, enabling reproducible data generation that can be scaled from the bench to the factory floor. By treating crystallization as a controlled data problem rather than a trial-and-error sequence, manufacturers are aiming to reduce the risk of late-stage failures in drug substance development.